Cannabinoid

MariMed’s Betty’s Eddies™ Celebrates a Decade of Handcrafted Deliciousness by Introducing a Limited-Edition Betty’s Bubbly Champagne Chew

Retrieved on: 
Monday, December 18, 2023
Family, THCV, Vitamin, Cannabinoid, Vegetable, Friends, Holiday, Taste, Weather, Health, Love, Immunity, Patient, Film industry

To celebrate the occasion, this month the brand is launching Betty’s Bubbly, a new, limited-edition batch of sparkling champagne chews.

Key Points: 
  • To celebrate the occasion, this month the brand is launching Betty’s Bubbly, a new, limited-edition batch of sparkling champagne chews.
  • Whether dancing the night away or home for the holidays, Betty’s Bubbly is the perfect companion for celebration.
  • Like all flavors in the Betty’s Eddies line-up, Betty’s Bubbly is made with love in small batches, using organic fruits and vegetables, supporting cannabinoids, and herbal supplements and vitamins.
  • Betty’s Bubbly follows the success of other recent seasonal flavors in the Betty’s Eddies line-up, including this past autumn’s Sweater Weather Betty’s offering and Beachtime Betty’s this past summer.

Malachite Innovations Changes its Name to Range Impact and Adopts New Ticker Symbol “RNGE”

Retrieved on: 
Thursday, December 14, 2023
Range Land, Water, Malachite, Cannabinoid, Acquisition, File, Mining, Terra preta, Ulcerative colitis, Growth, Environment, Marketing

“Malachite” is a green butterfly that was selected to symbolize our focus on both the environment and cannabinoids.

Key Points: 
  • “Malachite” is a green butterfly that was selected to symbolize our focus on both the environment and cannabinoids.
  • Range Minerals, through its wholly owned operating business, Range Natural Resources, Inc., provides land reclamation and incidental mining services to mining companies throughout Appalachia.
  • Range Security, through its wholly owned operating business, Range Security Resources, LLC, provides eco-friendly, technology-driven security services to active and former mine sites located in Appalachia.
  • In connection with this name change, Range Impact has a new trading symbol (RNGE) and a new website which can be found at: www.rangeimpact.com.

Boston Hemp Inc. Unveils Groundbreaking Exotic THCa Flower, Redefining Cannabis Experience

Retrieved on: 
Thursday, December 14, 2023
Tetrahydrocannabinolic acid, Cannabinoid, Decarboxylation, Smoking, THC, IBN, THCA, Drug

BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- via IBN -- Boston Hemp Inc., a pioneering force in the cannabis industry, proudly announces the launch of its latest innovation — the Exotic THCa Flower.

Key Points: 
  • BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- via IBN -- Boston Hemp Inc., a pioneering force in the cannabis industry, proudly announces the launch of its latest innovation — the Exotic THCa Flower.
  • Derived from meticulously cultivated hemp plants, Boston Hemp Inc.'s Exotic THCa Flower boasts an extraordinary profile of Tetrahydrocannabinolic Acid (THCa), a non-psychoactive precursor to THC that is fully activated once smoked or "decarbed" (decarboxylation).
  • Key features of Boston Hemp Inc.'s THCa Exotic Flower include:
    Exceptional Purity: Through advanced cultivation practices, the Exotic THCa Flower achieves exceptional levels of purity, ensuring a clean and unadulterated cannabis experience.
  • Boston Hemp Inc. invites enthusiasts, retailers and industry professionals to explore the transformative potential of the THCa Exotic Flower.

Hemp, Inc. Reports: 2018 Farm Bill Sees One-Year Extension Through 2024

Retrieved on: 
Tuesday, December 12, 2023
Senate, Cannabinoid, Ground substance, Controlled Substances Act, Farmer, Absorption, United States farm bill, Legislation, CBG, News, Rest, Democrat, Coffee, Republican, OTC, House

According to reports, the “extension of the 2018 Farm Bill involves its inclusion in a stopgap spending bill.”  Released by U.S. House Republicans, this bill intends to extend the 2018 Farm Bill through September 30, 2024.

Key Points: 
  • According to reports, the “extension of the 2018 Farm Bill involves its inclusion in a stopgap spending bill.”  Released by U.S. House Republicans, this bill intends to extend the 2018 Farm Bill through September 30, 2024.
  • The extension, while good news, is not “intended as a substitute for passing a comprehensive 5-year Farm Bill” but “leaders of the House and Senate Agriculture Committees have expressed their commitment to working together to accomplish this” in the upcoming year.
  • ( Source ) “We want to get the Farm Bill done as soon as possible, hopefully before the end of [next] year,” Senator Boozman said.
  • Boozman had previously stated that the extension wouldn’t prevent lawmakers from passing a bill sooner than the end of 2024.

Life Is Chill Expands Line of THC Soft Gels with New Live Resin THC Capsules, A First Of Its Kind for the Arizona Market

Retrieved on: 
Thursday, December 28, 2023
Technology, Biotechnology, Men, Nanotechnology, Alternative Medicine, Retail, Health, Cannabis, Consumer, Other Retail, General Health, Other Consumer, Natural Resources, Women, Cannabinoid, Acquisition, Capsule, Chill Pill, Life, THC, Allergy, Gelatin

The launch of live resin capsules marks a new era for soft gels in the Arizona market and will meet the increasing demand for products made from fresh-frozen cannabis.

Key Points: 
  • The launch of live resin capsules marks a new era for soft gels in the Arizona market and will meet the increasing demand for products made from fresh-frozen cannabis.
  • “We are honored to kick off the launch of these live resin soft gels, a first of its kind in the Arizona market,” said Steve Shapiro, founder and CEO of The Superior Dispensary.
  • The new product launch follows Ally Biotech’s acquisition of the Chill Pill line in the spring of 2023.
  • It continues the company’s plan to expand its product line and establish itself as a market leader in the soft gel category.

BioWellnessX Enters the Exotic THCa Flower Wholesale Market with a Diverse Range of Elite THCa Flowers

Retrieved on: 
Thursday, December 28, 2023
THCA, Elite, Relaxation, Cannabinoid, Rejuvenation, Education

BiowellnessX has consistently demonstrated a commitment to innovation, and the introduction of the Elite High-End Exotic THCa Flower is a testament to the ongoing efforts to provide the best in natural solutions.

Key Points: 
  • BiowellnessX has consistently demonstrated a commitment to innovation, and the introduction of the Elite High-End Exotic THCa Flower is a testament to the ongoing efforts to provide the best in natural solutions.
  • The company's newly introduced Elite THCa flower line boasts a diverse selection of potent and exotic strains, each distinct for its unique characteristics and euphoric effects.
  • "Our mission is to provide the most elite, top-shelf THCa flower options possible, backed by the unrivaled quality BioWellnessX is known for"
    BioWellnessX's premium THCa flower strains are meticulously curated to cater to diverse tastes and needs.
  • To explore their new line of elite THCa flower strains, please contact or visit the THCa flower wholesale form to get your wholesale account approved.

SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation

Retrieved on: 
Wednesday, November 15, 2023
Sophie, Hypotension, Cannabinoid, Alzheimer's disease, Eating, IMCA, Delirium, FDA, Agitation, Dronabinol, Tolerability, MD, CMAI, Central nervous system, Pharmaceutical industry, Medical device, Hospital, Disease, Patient, Safety

Tel-Aviv, Nov. 15, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), unveiled positive topline results from its investigator-initiated Phase IIa trial at the Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center (IMCA). The trial results indicated that SciSparc’s proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients who participated.

Key Points: 
  • The trial results indicated that SciSparc’s proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients who participated.
  • Agitation is a devastating symptom of Alzheimer's Disease (AD), afflicting nearly all patients as the disease progresses, and imposing tremendous suffering and caregiving burdens.
  • The results not only met primary endpoints regarding tolerability and adverse events but also demonstrated SCI-110's potential to alleviate agitation without side effects.
  • Moreover, when measured by the Cohen Mansfield Agitation Inventory (CMAI), our treatment led to a significant 23% reduction in agitation symptoms.

Rubicon Organics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Sale, Foot, Cannabinoid, Comatose, Budtender, Super Lemon Haze, THC, White rainbow, Conference call, CBN, Delta, Rubicon, Conference, Adjustment, Smell, Partnership, Table, Growth, Overalls, Information, CBG, Tea, Rare-earth element, Airline, CBD

Following up on the success of the initial two flavour launch in the second quarter, 1964 Supply CoTM has rolled out three additional flavours.

Key Points: 
  • Following up on the success of the initial two flavour launch in the second quarter, 1964 Supply CoTM has rolled out three additional flavours.
  • In October 2023, Simply Bare TM Organic launched a new 2-gram hash, “New School Hash” available in BC, Ontario, Alberta and Quebec.
  • Rubicon Organics has set out four key priorities for 2023:
    Our priority is delivering super-premium quality cannabis flower products in the Canadian market.
  • The Company will be hosting a conference call to discuss Q3 2023 results on Wednesday, November 15, 2023.

Avicanna Reports Q3 2023 Results

Retrieved on: 
Tuesday, November 14, 2023
EBITDA, FSE, Cannabinoid, Therapy, CFO, Stock, Insurance, Patient, Broad-spectrum therapeutic, Shoppers Drug Mart, Growth, Development, TSX, Education, Medical cannabis, Pharmaceutical industry, Video game, Q2

TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the commercialization of proprietary cannabinoid-based products and medical cannabis care platform is pleased to announce the results of Q3 2023.

Key Points: 
  • TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the commercialization of proprietary cannabinoid-based products and medical cannabis care platform is pleased to announce the results of Q3 2023.
  • A 9-month revenue of $10.7M, representing a major milestone in the Company’s history a 269% growth from the same period last year.
  • Scalability of the business model was demonstrated with a comparable increase of 23% in SG&A for the nine-month period.
  • Access to the Company’s proprietary medical products improved for patients with availability on new medical platforms such as Canna Farms and Spectrum Therapeutics.

SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication

Retrieved on: 
Friday, November 10, 2023
Ministry, Safety, TS, Food, Yale University, Disorder, THC, Clinical trial, Medical device, Patient, IIA, FDA, Movement, Hannover Medical School, Cannabinoid, Tourette syndrome, Learning, Central nervous system, Tic, TEL, PEA, Pharmaceutical industry, Dronabinol, Health

TEL AVIV, Israel, Nov. 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced the initiation of its Phase IIb clinical trial treating patients suffering from Tourette Syndrome (TS) with its SCI-110, proprietary drug candidate.

Key Points: 
  • SciSparc initiated the trial at the Tel Aviv Sourasky Medical Center in Israel (Sourasky) and is expected to proceed with its U.S. and Germany-based medical sites.
  • TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co-morbidities.
  • The patients will be randomized at a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.
  • In addition, the medication was generally well-tolerated by subjects and 12 out of the 16 subjects elected to continue into a 24-week extension phase of the trial.